Ujvira 160mg Injection

About

Ujvira 160mg Injection is a biological medication, likely a biosimilar to trastuzumab, a recombinant humanized monoclonal antibody that selectively targets the human epidermal growth factor receptor 2 (HER2) protein. HER2 is overexpressed in certain aggressive types of breast cancer and gastric cancer, promoting uncontrolled cell growth and division. By binding to the extracellular domain of the HER2 receptor, trastuzumab inhibits HER2-mediated signaling pathways, leading to reduced cell proliferation, increased apoptosis, and enhanced immune-mediated destruction of tumor cells. It is a cornerstone of targeted therapy for HER2-positive malignancies.

This targeted approach allows for more specific treatment with potentially fewer side effects compared to conventional chemotherapy, although cardiotoxicity is a notable concern requiring careful monitoring. Ujvira is typically used in combination with chemotherapy or as a single agent in patients with HER2-positive metastatic disease, and as adjuvant therapy after surgery for early breast cancer. Its introduction has significantly improved the prognosis for patients with HER2-positive cancers.

Uses

• Treatment of HER2-positive early breast cancer.
• Treatment of HER2-positive metastatic breast cancer.
• Treatment of HER2-positive metastatic gastric cancer.
• Adjuvant therapy after surgery for early breast cancer.

Directions For Use

Administered intravenously by a healthcare professional, typically weekly or every three weeks, as directed by a physician.

Benefits

• Targets HER2-positive cancers specifically.
• Inhibits tumor cell growth and proliferation.
• Improves survival rates in HER2-positive patients.
• Used in combination with chemotherapy.
• Reduces risk of cancer recurrence.
• Enhances immune response against tumor cells.

Side Effects

• Cardiotoxicity (e.g., congestive heart failure, decreased LVEF).
• Infusion-related reactions (fever, chills, nausea).
• Diarrhea.
• Nausea and vomiting.
• Headache.
• Fatigue.
• Rash.
• Myalgia.
• Neutropenia.
• Anemia.
• Peripheral neuropathy.
• Pulmonary toxicity (e.g., interstitial pneumonitis).

Safety Measures

• Alcohol - No specific contraindication, but avoid excessive alcohol due to potential for general health decline during cancer treatment.
• Pregnancy - Contraindicated in pregnancy due to potential for fetal harm (oligohydramnios, renal hypoplasia); effective contraception is required.
• Breastfeeding - Not recommended during breastfeeding as it may be excreted in breast milk and cause adverse effects in the infant.
• Liver - Use with caution in patients with severe hepatic impairment; monitor liver function closely.
• Kidney - Use with caution in patients with renal impairment; monitor kidney function.
• Lung - Use with caution in patients with pre-existing pulmonary disease; monitor for pulmonary toxicity (e.g., dyspnea, cough).

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.